Delayed cerebral vasospasm after subarachnoid hemorrhage (SAH) remains a significant
cause of mortality and morbidity; however, the etiology is, as yet, unknown, despite intensive …

Background Thrombectomy is currently recommended for eligible patients with stroke who
are treated within 6 hours after the onset of symptoms. Methods We conducted a multicenter, …

Background Endovascular therapy is increasingly used after the administration of intravenous
tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic …

Background and Purpose— Intracerebral hemorrhage (ICH) has a 30-day mortality rate of
40% to 50% and lacks a proven treatment. We report a preplanned, midpoint analysis of the …

Background The IMS III trial did not show a clinical benefit of endovascular treatment
compared with intravenous alteplase (recombinant tissue plasminogen activator) alone for …

Ischemic brain and peripheral white blood cells release cytokines, chemokines and other
molecules that activate the peripheral white blood cells after stroke. To assess gene …

Background and Purpose— Subarachnoid hemorrhage (SAH) caused by ruptured intracranial
aneurysm affects approximately 16 000 Americans annually, and almost 40% of affected …

Background and Purpose— Endovascular strategies provide unique opportunity to correlate
angiographic measures of collateral circulation at the time of endovascular therapy. We …

Rationale The Interventional Management of Stroke (IMS) I and II pilot trials demonstrated
that the combined intravenous (iv) and intraarterial (ia) approach to recanalization may be …

Background and Purpose— The acute stroke literature lacks a standard convention
regarding the critical end point of revascularization. Two distinct parameters may be clinically …